Maria Theresa Cabe, MD
Family Medicine · Fort Wayne, INNPI 1336187335
Payments from drug & device makers
Across 250 payments — averaging $16.62 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Lilly USA, LLC$715
- AstraZeneca$590
- Novo Nordisk$554
- Boehringer Ingelheim$381
- AbbVie$346
- GSK$167
- plus $1K from 20 others
What the payments were for
- Food & beverage$4,155100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Lilly USA, LLC | 39 | $715 |
| AstraZeneca | 29 | $590 |
| Novo Nordisk | 50 | $554 |
| Boehringer Ingelheim | 19 | $381 |
| AbbVie | 22 | $346 |
| GSK | 11 | $167 |
| Bayer | 6 | $154 |
| Amgen | 9 | $139 |
| Sanofi-aventis U.S. LLC | 8 | $132 |
| Amarin Pharma, Inc. | 8 | $126 |
| Exact Sciences | 7 | $117 |
| Astellas Pharma US Inc | 6 | $116 |
| Merck | 6 | $92 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 6 | $89 |
| Takeda Pharmaceuticals U.S.A., Inc. | 4 | $73 |
| Pfizer | 3 | $57 |
| Abbott | 3 | $53 |
| Johnson & Johnson | 3 | $51 |
| Axsome Therapeutics, Inc. | 2 | $45 |
| Corcept Therapeutics | 2 | $43 |
| Eisai Inc. | 2 | $32 |
| Phathom Pharmaceuticals, Inc. | 1 | $19 |
| Biohaven Pharmaceuticals, Inc. | 1 | $18 |
| Ultragenyx Pharmaceutical Inc. | 1 | $17 |
| Esperion Therapeutics, Inc. | 1 | $14 |
| Sumitomo Pharma America, Inc. | 1 | $14 |
How this compares
$4,155 in reported general payments places this provider in the 80th percentile of 2,709 family medicine providers in Indiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MounjaroTirzepatide | 179 | $210,945 |
| JardianceEmpagliflozin | 102 | $148,810 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 66 | $91,716 |
| FarxigaDapagliflozin Propanediol | 73 | $73,732 |
| EliquisApixaban | 72 | $65,920 |
| TradjentaLinagliptin | 47 | $63,657 |
| OzempicSemaglutide | 50 | $51,691 |
| JanuviaSitagliptin Phosphate | 21 | $29,737 |
| XareltoRivaroxaban | 20 | $28,013 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 23 | $26,818 |
| TrulicityDulaglutide | 20 | $22,513 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 25 | $21,545 |
| Tresiba Flextouch U-200Insulin Degludec | 31 | $20,882 |
| RybelsusSemaglutide | 12 | $19,147 |
| Tresiba Flextouch U-100Insulin Degludec | 27 | $12,228 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro, Trulicity | $715 | $233,458199 claims |
| Boehringer IngelheimJardiance, Tradjenta, Stiolto Respimat | $381 | $220,834167 claims |
| GSKTrelegy Ellipta, Anoro Ellipta, Breo Ellipta | $167 | $118,308103 claims |
| AstraZenecaFarxiga | $590 | $73,73273 claims |
| Novo NordiskOzempic, Rybelsus | $554 | $70,83862 claims |
| PfizerEliquis | $57 | $65,92072 claims |
| MerckJanuvia | $92 | $29,73721 claims |
| Johnson & JohnsonXarelto | $51 | $28,01320 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 2,709 family medicine providers in Indiana.
Other family medicine in Fort Wayne
- Thomas KintanarFort Wayne$185K
- Brianna SerbusFort Wayne$174K
- Brian AdamsFort Wayne$173K
- Charles CoatsFort Wayne$38K
- Beulah PenumudiFort Wayne$38K
- Blair BrengleIndianapolis$10.6M
- Laura HelmanMishawaka$4M
- J Christopher SartoreEvansville$3.9M
- Hubert ReyesEvansville$3.2M
- David SchultzEvansville$3M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.